

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
6 May 2005 (06.05.2005)

PCT

(10) International Publication Number
WO 2005/040100 A1

(51) International Patent Classification⁷: **C07C 275/32**,
275/38, 275/30, C07D 317/66, 261/14, 213/40, 213/89,
285/06, 209/18, C07C 235/56, 233/75, 237/04, 235/16,
213/56, C07D 215/46

(21) International Application Number:
PCT/EP2004/011008

(22) International Filing Date: 2 October 2004 (02.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

03023288.8	15 October 2003 (15.10.2003)	EP
03023287.0	15 October 2003 (15.10.2003)	EP
03025573.1	8 November 2003 (08.11.2003)	EP
03025572.3	8 November 2003 (08.11.2003)	EP

(71) Applicant (for all designated States except US): **BAYER HEALTHCARE AG** [DE/DE]; 51368 Leverkusen (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BOUCHON**, Axel [DE/DE]; Rabenweg 69, 42115 Wuppertal (DE). **DIEDRICH**, Nicole [DE/DE]; Laurentiusstr. 12, 42103 Wuppertal (DE). **HERMANN**, Achim [DE/DE]; Ackerstr. 150, 40233 Düsseldorf (DE). **LUSTIG**, Klemens [DE/DE]; Falkenberg 159, 42113 Wuppertal (DE). **MEIER**, Heinrich [DE/DE]; Claudiusweg 3, 42115 Wuppertal (DE). **PERNERSTORFER**, Josef [AT/DE]; Gerresheimer Str. 9, 40721 Hilden (DE). **REIBMÜLLER**, Elke [DE/DE]; Palkestr. 5, 42115 Wuppertal (DE). **MOGI**, Muneto [JP/JP]; 5-10-57-102, Daianji, Nara-shi, Nara 630-8133 (JP). **YURA**, Takeshi [JP/JP]; 4-8-1, Suzaku, Nara-shi, Nara 631-0806 (JP). **FUJISHIMA**, Hiroshi [JP/JP]; 3-23-25, Sakyo, Nara-shi, Nara 631-0801 (JP). **SEKI**, Masaomi [JP/JP]; Sanjo-Sakaemachi, Nara-shi, Nara 630-8126 (JP). **KORIYAMA**, Yuji [JP/JP]; 5-13-6-102, Jingu, Nara-shi, Nara 630-0804 (JP). **YASOSHIMA**, Kayo [JP/JP]; 1352-3-201, Hokkeji-cho, Nara-shi, Nara 630-8001 (JP). **MISAWA**, Keiko [JP/JP]; 4-1-201, Kitafuro-cho, Nara-shi, Nara

630-8552 (JP). **TAJIMI**, Masaomi [JP/JP]; 1-8-17, Sakuragaoka, Seika-cho, Soraku-gun, Kyoto 619-0232 (JP). **YAMAMOTO**, Noriyuki [JP/JP]; 6-6-1-3-404, Jungu, Nara-shi, Nara 631-0804 (JP). **URBAHNS**, Klaus [DE/SE]; Martenstorget 8, S-22351 Lund (SE). **HAYASHI**, Fumihiko [JP/JP]; 19-12, Kamishakuji minami-cho, Nerima-ku, Tokyo 177-0043 (JP). **TSUKIMI**, Yasuhiro [JP/JP]; 2-10-6, Shimosakabe, Amagasaki-shi, Hyogo 661-0975 (JP). **GUPTA**, Jang [IN/DE]; Rheinbrohler Weg 15, 40489 Düsseldorf (DE).

(74) Common Representative: **BAYER HEALTHCARE AG**; Law and Patents, Patents and Licensing, 51368 Leverkusen (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES**

(57) Abstract: This invention relates to tetrahydro-naphthalene and urea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The tetrahydro-naphthalene and urea derivatives of the present invention have vanilloid receptor (VR1) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urological diseases or disorders, such as detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor overactivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms; chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, and inflammatory disorders such as asthma and chronic obstructive pulmonary (or airways) disease (COPD). BHC 03 2 001-Foreign-Countries - 66 - BHC 03 2 001-Foreign-Countries - 65 -



WO 2005/040100 A1